PMID- 32486227
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 12
IP  - 6
DP  - 2020 May 30
TI  - Efficacy and Safety of Oncolytic Viruses in Randomized Controlled Trials: A 
      Systematic Review and Meta-Analysis.
LID - 10.3390/cancers12061416 [doi]
LID - 1416
AB  - Oncolytic virotherapy is a promising antitumor therapeutic strategy. It is based 
      on the ability of viruses to selectively kill cancer cells and induce host 
      antitumor immune responses. However, the clinical outcomes of oncolytic viruses 
      (OVs) vary widely. Therefore, we performed a meta-analysis to illustrate the 
      efficacy and safety of oncolytic viruses. The Cochrane Library, PubMed, and 
      EMBASE databases were searched for randomized controlled trials (RCTs) published 
      up to January 31, 2020. The data for objective response rate (ORR), overall 
      survival (OS), progression-free survival (PFS), and adverse events (AEs) were 
      independently extracted by two investigators from 11 studies that met the 
      inclusion criteria. In subgroup analyses, the objective response rate benefit was 
      observed in patients treated with oncolytic DNA viruses (odds ratio (OR) = 4.05; 
      95% confidence interval (CI): 1.96-8.33; p = 0.0002), but not in those treated 
      with oncolytic RNA viruses (OR = 1.00, 95% CI: 0.66-1.52, p = 0.99). Moreover, 
      the intratumoral injection arm yielded a statistically significant improvement 
      (OR = 4.05, 95% CI: 1.96-8.33, p = 0.0002), but no such improvement was observed 
      for the intravenous injection arm (OR = 1.00, 95% CI: 0.66-1.52, p = 0.99). Among 
      the five OVs investigated in RCTs, only talimogene laherparepvec (T-VEC) 
      effectively prolonged the OS of patients (hazard ratio (HR), 0.79; 95% CI: 
      0.63-0.99; p = 0.04). None of the oncolytic virotherapies improved the PFS (HR = 
      1.00, 95% CI: 0.85-1.19, p = 0.96). Notably, the pooled rate of severe AEs (grade 
      >/=3) was higher for the oncolytic virotherapy group (39%) compared with the 
      control group (27%) (risk difference (RD), 12%; risk ratio (RR), 1.44; 95% CI: 
      1.17-1.78; p = 0.0006). This review offers a reference for fundamental research 
      and clinical treatment of oncolytic viruses. Further randomized controlled trials 
      are needed to verify these results.
FAU - Li, Zengbin
AU  - Li Z
AD  - Department of Medical Microbiology, School of Medicine, Nanchang University, 
      Nanchang 330006, China.
AD  - School of Public Health, Nanchang University, Nanchang 330006, China.
FAU - Jiang, Zeju
AU  - Jiang Z
AD  - Department of Medical Microbiology, School of Medicine, Nanchang University, 
      Nanchang 330006, China.
FAU - Zhang, Yingxuan
AU  - Zhang Y
AD  - Department of Medical Microbiology, School of Medicine, Nanchang University, 
      Nanchang 330006, China.
FAU - Huang, Xiaotian
AU  - Huang X
AD  - Department of Medical Microbiology, School of Medicine, Nanchang University, 
      Nanchang 330006, China.
AD  - Key Laboratory of Tumor Pathogenesis and Molecular Pathology, School of Medicine, 
      Nanchang University, Nanchang 330006, China.
FAU - Liu, Qiong
AU  - Liu Q
AD  - Department of Medical Microbiology, School of Medicine, Nanchang University, 
      Nanchang 330006, China.
AD  - Key Laboratory of Tumor Pathogenesis and Molecular Pathology, School of Medicine, 
      Nanchang University, Nanchang 330006, China.
LA  - eng
GR  - 31760261 and 31660035/National Natural Science Foundation of China/
GR  - 60224/Science and Technology Research Project of Jiangxi Provincial Education 
      Department/
GR  - 20192BBG70067/Key Research and Development Projects of Jiangxi Natural Science 
      Foundation/
GR  - 20190403070/National College Students Innovation and Entrepreneurship Training 
      Program/
GR  - 20171ACB20003/Key Projects of Jiangxi Natural Science Foundation/
PT  - Journal Article
PT  - Review
DEP - 20200530
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC7352817
OTO - NOTNLM
OT  - adverse events
OT  - efficacy
OT  - meta-analysis
OT  - oncolytic virotherapy
OT  - oncolytic viruses
OT  - systematic review
COIS- The authors declare that they have no conflict of interest
EDAT- 2020/06/04 06:00
MHDA- 2020/06/04 06:01
PMCR- 2020/05/30
CRDT- 2020/06/04 06:00
PHST- 2020/04/22 00:00 [received]
PHST- 2020/05/26 00:00 [revised]
PHST- 2020/05/27 00:00 [accepted]
PHST- 2020/06/04 06:00 [entrez]
PHST- 2020/06/04 06:00 [pubmed]
PHST- 2020/06/04 06:01 [medline]
PHST- 2020/05/30 00:00 [pmc-release]
AID - cancers12061416 [pii]
AID - cancers-12-01416 [pii]
AID - 10.3390/cancers12061416 [doi]
PST - epublish
SO  - Cancers (Basel). 2020 May 30;12(6):1416. doi: 10.3390/cancers12061416.